![Full Text of PDF](img/ico_pdf_full.gif)
Article in Japanese
Efficacy of recombinant human thrombomodulin α in acute exacerbation of idiopathic pulmonary fibrosis
Takefumi Abea Koshi Yokomuraa Ayano Gotoa Daisuke Akahoria Keigo Koudaa Takafumi Koyauchia Takuya Kakutania Yasunori Enomotoa Takashi Matsuia Takafumi Sudab
aDepartment of Respiratory Medicine, Respiratory Disease Center, Seirei Mikatahara General Hospital
bSecond Department of Internal Medicine, Hamamatsu University School of Medicine
There is no effective therapy for acute exacerbation of idiopathic pulmonary fibrosis. Recently, it has been suggested that the pathology of acute exacerbation of idiopathic pulmonary fibrosis is indicative of hypercoagulable status. We studied the efficacy of recombinant human thrombomodulin (rhTM) α for acute exacerbation of idiopathic pulmonary fibrosis. Of a total of 29 patients, we retrospectively compared the background and prognosis between the 12 patients in the rhTM-administered group and the 17 patients in the non-rhTM-administered group. One- and three-month-survival rates of the groups were 75% and 67% in the rhTM-administered group and 46% and 40% in the non-rhTM-administered group, respectively (log-rank test, p=0.154). Bleeding complications in the rhTM-administered group were not observed. Recombinant human thrombomodulin α has the possibility of improving prognosis in acute exacerbation of idiopathic pulmonary fibrosis.
Idiopathic pulmonary fibrosis Acute exacerbation Recombinant human thrombomodulin α Hypercoagulability
Received 23 Jun 2015 / Accepted 16 Nov 2015
AJRS, 5(2): 57-63, 2016